MedTrace Logo

A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas

NCT01112384 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-08-04

No results posted yet for this study

Summary

The purpose of this study is to find out what effects a new drug SB939 has on you and your sarcoma.

This research is being done because there is a need for better treatment options for advanced or recurring sarcoma.

SB939 has been shown to shrink tumours in animals and some people and seems promising but it is not clear if it has any positive effects in sarcoma.

Conditions

  • Metastatic Sarcoma

Interventions

DRUG

SB939

Given orally 3 times per week

Sponsors & Collaborators

  • S*BIO

    collaborator INDUSTRY

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Quincy Chu · Cross Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-21
Primary Completion
2013-01-21
Completion
2014-01-16

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01112384 on ClinicalTrials.gov